The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
Abstract
Bile acid sequestrants can potentially bind to concomitant drugs. Single-dose studies evaluated the effects of colesevelam on the pharmacokinetics of glimepiride, glipizide extended-release (ER), and olmesartan medoxomil. Each study enrolled healthy subjects aged 18-45 years. The olmesartan medoxomil study used a randomized adaptive crossover design that initially compared olmesartan medoxomil alone versus simultaneously with colesevelam, then olmesartan medoxomil alone versus 4 hours before colesevelam. The other studies used a three-period crossover design (test drug alone, test drug simultaneou...
Source: The Journal of Clinical Pharmacology - September 10, 2013 Category: Drugs & Pharmacology Authors: He L, Wickremasingha P, Lee J, Tao B, Mendell-Harary J, Walker J, Wight D Tags: J Clin Pharmacol Source Type: research
Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST Study at 16 weeks
hi
& K Shimada (Source: Journal of Human Hypertension)
Source: Journal of Human Hypertension - July 18, 2013 Category: Cardiology Authors: K KarioI SaitoT KushiroS TeramukaiY IshikawaK HiramatsuF KobayashiK Shimada Tags: angiotensin receptor antagonists clinic blood pressure home blood pressure monitoring morning hypertension olmesartan medoxomil Source Type: research
Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis
Conclusion:Overall, the combination of olmesartan and HCTZ is as effective as olmesartan and CCB in lowering 24-h, daytime, and night-time ambulatory BP. However, greater lowering is noted with the olmesartan and CCB combination for clinic BP. Thus, out-of-office BP monitoring is necessary to provide better assessment of overall BP and response to treatment. Women and diabetic individuals may have slightly better 24-h ambulatory BP response with the olmesartan and CCB combination therapy. (Source: Journal of Hypertension)
Source: Journal of Hypertension - July 8, 2013 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research
Olmesartan/Amlodipine/Hydrochlorothiazide in Obese Participants With Hypertension: A TRINITY Subanalysis
The objective of this prespecified TRINITY study subgroup analysis was to assess the efficacy and safety of triple‐combination treatment with olmesartan medoxomil (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg vs the component dual‐combination treatments in obese (body mass index [BMI] ≥30 kg/m2) and nonobese (BMI <30 kg/m2) hypertensive participants. The double‐blind treatment period primary end point was the least‐squares (LS) mean reduction in seated diastolic BP (SeDBP) at week 12 (end of the double‐blind period). Of the 2492 randomized participants, 1555 (62.4%) h...
Source: The Journal of Clinical Hypertension - June 4, 2013 Category: Cardiology Authors: Eli M. Roth, Suzanne Oparil, Michael Melino, James Lee, Victor Fernandez, Reinilde Heyrman Tags: Original Paper Source Type: research
Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension
In this study, 157 resistant hypertension patients older than 60 years were randomized to 8 weeks double-blind treatment with placebo, AML 10mg/day, OM 40mg/day and AM×L (10mg/day)+OM (40mg/day). Research outcomes suggested that ALM+OM combination therapy had superior efficacy than ALM or OM monotherapies in terms of the clinic blood pressure and 24-h ambulatory blood pressure. In addition, more patients receiving combination therapy (62.5%) achieved BP goal than those treated with placebo (18.4%), AML (37.5) or OM (38.5%) monotherapies. The adverse events in both groups were comparable. Thus, the combination of AML+OM pr...
Source: Archives of Gerontology and Geriatrics - May 13, 2013 Category: Geriatrics Authors: Shunjing Ding, Jin Liu, Qiang Fu, Ying Zheng Source Type: research
Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rats.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) driven through altered immune responses with production of proinflammatory cytokines. Many therapies are used, but side effects and loss of response limit long-term effectiveness. New therapeutic strategies are thus needed for patients who don't respond to current treatments. Recently, there is suggested involvement of the proinflammatory hormone angiotensin II in inflammatory bowel disease. The aim of this study was to investigate the possible role of olmesartan medoxomil (OLM-M), an angiotensin II receptor blocker in ameliorat...
Source: Toxicology and Applied Pharmacology - May 9, 2013 Category: Toxicology Authors: Nagib MM, Tadros MG, Elsayed MI, Khalifa AE Tags: Toxicol Appl Pharmacol Source Type: research
Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive.
CONCLUSIONS: The combination of azilsartan medoxomil/chlorthalidone has demonstrated safety and efficacy in lowering BP in hypertensive patients to a greater degree than olmesartan medoxomil/hydrochlorothiazide and azilsartan medoxomil/hydrochlorothiazide. As a fixed-dose combination tablet, it offers several clinical advantages.
PMID: 23585646 [PubMed - in process] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - May 1, 2013 Category: Drugs & Pharmacology Authors: Pierini D, Anderson KV Tags: Ann Pharmacother Source Type: research
Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
CONCLUSIONS: Our study highlights the independent regulation of RAS among plasma, heart, and kidney tissue in response to AT(1)-R blockade. Ang-(1-7) through the mas receptor does not mediate long-term effects of olmesartan besides counterbalancing renin release in response to AT(1)-R blockade.
PMID: 23459599 [PubMed - in process] (Source: American Journal of Hypertension)
Source: American Journal of Hypertension - May 1, 2013 Category: Cardiology Authors: Varagic J, Ahmad S, VonCannon JL, Moniwa N, Brosnihan KB, Wysocki J, Batlle D, Ferrario CM Tags: Am J Hypertens Source Type: research
Olmesartan: Induced maculopapular rash
Aruna Bhushan, ST Ved BhushanIndian Journal of Pharmacology 2013 45(2):199-200Olmesartan medoxomil is an angiotensin receptor blocker (ARB) which is shown to be effective and well tolerated in hypertensive patients. It is a frequently prescribed antihypertensive as it is considered safe. Here, we report the case of a patient who developed maculopapular rash during the course of the treatment with olmesartan medoxomil. (Source: Indian Journal of Pharmacology)
Source: Indian Journal of Pharmacology - March 11, 2013 Category: Drugs & Pharmacology Authors: Aruna BhushanST Ved Bhushan Source Type: research
Antihypertensive Efficacy of Olmesartan Medoxomil and Ramipril in Elderly Patients with Mild to Moderate Hypertension Grouped According to Renal Function Status: A Retrospective Analysis
(Source: High Blood Pressure)
Source: High Blood Pressure - February 7, 2013 Category: Cardiology Authors: Malacco, EttoreOmboni, StefanoMallion, Jean-MichelVolpe, Massimo Tags: Original Research Articles Source Type: research
Hematemesis in a Man With Longstanding Esophageal Globus Sensation
Question: An 81-year-old man with a long history of experiencing a globus sensation over the suprasternal area was admitted for massive hematemesis. He denied alcohol or tobacco use, but was taking medication for diabetes mellitus, dyslipidemia, and hypertension. His medicines included glimepiride, acarbose, atorvastatin, and olmesartan medoxomil. (Source: Gastroenterology)
Source: Gastroenterology - February 4, 2013 Category: Gastroenterology Authors: Chia-Wei Yang, Hsu-Heng Yen, Chung-Ho Choo Tags: Electronic Clinical Challenges and Images in GI Source Type: research
Efficacy/Safety of a Fixed‐Dose Amlodipine/Olmesartan Medoxomil–Based Treatment Regimen in Hypertensive Blacks and Non‐Blacks With Uncontrolled BP on Prior Antihypertensive Monotherapy
In this secondary analysis of a dose‐titration study of patients with hypertension uncontrolled on prior monotherapy, blacks (n=234) and non‐blacks (n=765) were switched to amlodipine (AML)/olmesartan medoxomil (OM) 5/20 mg, with uptitration every 4 weeks to AML/OM 5/40 mg and then AML/OM 10/40 mg to achieve a seated cuff blood pressure (SeBP) of <120/70 mm Hg. Hydrochlorothiazide 12.5 and 25 mg could be added if SeBP was ≥125/75 mm Hg. The cumulative proportions of patients achieving systolic SeBP <140 mm Hg (<130 mm Hg if diabetic) at 12 weeks were 71.6% for blacks and 77.2% for non‐blacks....
Source: The Journal of Clinical Hypertension - February 1, 2013 Category: Cardiology Authors: Shawna Nesbitt, Ali Shojaee, Jen‐Fue Maa Tags: Original Paper Source Type: research
The Case Files: Renal Infarct
Dubrovskiy, Aleksandr DO; Levy, David DO; Saadatmand, Babak MD
A 56-year-old man with a past medical history significant for hypertension, hyperlipidemia, and sciatica presented to the ED complaining of a sudden onset of sharp, severe, right flank pain radiating to his right groin. The pain began about 30 minutes prior to arrival and had been constant since onset. He denied any alleviating or aggravating factors, trauma, or prior occurrences.
He complained of nausea without vomiting, and review of systems was otherwise negative. He had no recent surgeries and denied any alcohol, smoking, or drug use. The patient was allerg...
Source: The Case Files - August 10, 2012 Category: Emergency Medicine Tags: Blog Posts Source Type: research
Efficacy/Safety of Olmesartan Medoxomil Versus Losartan Potassium in Patients by Stage 1 or 2 Hypertension
John M. Flack, MD, MPH; Alan Graff, MD; Wei Li, PhD; Kathleen J. Chavanu, PharmD
DOI: 10.3810/pgm.2012.05.2549
Abstract: An exploratory subgroup analysis of a prospective, randomized, double-blind, forced-titration study comparing the efficacy and safety of once-daily olmesartan medoxomil (OM) and losartan potassium (LOS) in patients with stage 1 or stage 2 hypertension is reported. After a 3- to 4-week placebo run-in period, eligible patients received once-daily OM (weeks 1–4, 20 mg; weeks 5–8, 40 mg), placebo plus OM (weeks 1–2, placebo; weeks 3–4, OM 20 mg; weeks 5–8, OM 40 mg), or LO...
Source: Postgraduate Medicine Online - June 4, 2012 Category: Internal Medicine Authors: admin Source Type: research
